Cysteine proteases as disease markers

被引:162
作者
Berdowska, I [1 ]
机构
[1] Wroclaw Med Univ, Dept Biochem Med, PL-50368 Wroclaw, Poland
关键词
cysteine cathepsins; cancer; periodontitis; arthritis; diagnostic markers; prognostic markers;
D O I
10.1016/j.cccn.2003.12.016
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
This review comprises issues concerning cysteine cathepsins (CCs): human peptidases belonging to papain family (C1) of clan CA of cysteine proteases: cathepsins B, L, H, S, K, F, V, X, W, O and C. The involvement of these enzymes in physiological and pathological processes is described, especially with respect to their application as diagnostic and prognostic markers. They participate in precursor protein activation (including proenzymes and prohormones), MHC-II-mediated antigen presentation, bone remodeling, keratinocytes differentiation, hair follicle cycle, reproduction and apoptosis. Cysteine cathepsins upregulation has been demonstrated in many human tumors, including breast, lung, brain, gastrointestinal, head and neck cancer, and melanoma. Besides cancer diseases, they have been implied to participate in inflammatory diseases, such as inflammatory myopathies, rheumatoid arthritis, and periodontitis. Also, certain hereditary disorders are connected with mutations in CCs genes, what is observed in pycnodysostosis resulted from catK gene mutation and Papillon-Lefevre and Haim-Munk syndrome caused by catC gene defect. The potential application of cysteine cathepsins in diagnosis and/or prognosis is discussed in cancer diseases (breast, lung, head and neck, ovarian, gastrointestinal cancers, melanoma), as well as other disorders (periodontitis, rheumatoid arthritis, osteoarthritis). (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:41 / 69
页数:29
相关论文
共 262 条
[21]  
Biroc SL, 2001, ARTHRITIS RHEUM, V44, P703, DOI 10.1002/1529-0131(200103)44:3<703::AID-ANR120>3.0.CO
[22]  
2-2
[23]   Involvement of cathepsin H in the processing of the hydrophobic surfactant-associated protein C in type II pneumocytes [J].
Brasch, F ;
ten Brinke, A ;
Johnen, G ;
Ochs, M ;
Kapp, N ;
Müller, KM ;
Beers, MF ;
Fehrenbach, H ;
Richter, J ;
Batenburg, JJ ;
Bühling, F .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2002, 26 (06) :659-670
[24]  
Bresnihan B, 1999, J RHEUMATOL, V26, P717
[25]   Evidence for extracellularly acting cathepsins mediating thyroid hormone liberation in thyroid epithelial cells [J].
Brix, K ;
Lemansky, P ;
Herzog, V .
ENDOCRINOLOGY, 1996, 137 (05) :1963-1974
[26]   Thiol-dependent cathepsins:: Pathophysiological implications and recent advances in inhibitor design [J].
Brömme, D ;
Kaleta, J .
CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (18) :1639-1658
[27]   Lymphopain, a cytotoxic T and natural killer cell-associated cysteine proteinase [J].
Brown, J ;
Matutes, E ;
Singleton, A ;
Price, C ;
Molgaard, H ;
Buttle, D ;
Enver, T .
LEUKEMIA, 1998, 12 (11) :1771-1781
[28]   Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma [J].
Budihna, M ;
Strojan, P ;
Smid, L ;
Skrk, J ;
Vrhovec, I ;
Zupevc, A ;
Rudolf, Z ;
Zargi, M ;
Krasovec, M ;
Svetic, B ;
KopitarJerala, N ;
Kos, J .
BIOLOGICAL CHEMISTRY HOPPE-SEYLER, 1996, 377 (06) :385-390
[29]   PROGNOSTIC VALUE OF TOTAL CATHEPSIN-B IN INVASIVE DUCTAL CARCINOMA OF THE BREAST [J].
BUDIHNA, M ;
SKRK, J ;
ZAKOTNIK, B ;
GABRIJELCIC, D ;
LINDTNER, J .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (05) :661-664
[30]  
Bühling F, 1999, AM J RESP CELL MOL, V20, P612